Biogen - חוב לטווח קצר של החברה BIIB

Biogen's stable income is ensured by patient dependence on therapies for rare diseases, while the shortfall in its own developments is compensated for by acquiring external licenses. The short-term debt chart shows the dynamics of current credit obligations, with the figure stabilizing at 1.37. The brand's high reputation in medicine is confirmed by its bold Alzheimer's research and the development of innovative brain treatments.

The indicator's dynamics depend directly on the balance between operating cash flows and current liabilities. This metric aggregates all debts due within twelve months to measure business liquidity. For Biogen Inc. (BIIB), this is critical when funding R&D and launching Leqembi into the market amid declining revenues from legacy drugs. An increase in short-term accounts payable signals a risk of capital deficiency. Analyze this short-term debt load to assess the sustainability of the restructuring.